Purpose: To evaluate the effect of left gastric artery embolization (LGAE) on glycated hemoglobin (HbA1c) in a prospective obese,
prediabetic cohort.
Materials and Methods: This prospective pilot study included 10 obese, prediabetic patients (7 females and 3 males; mean age 37.5
± 8.8 years; range 28–51 years) admitted to the Interventional Radiology Unit between January 2017 and June 2018 for LGAE for
weight reduction. The main inclusion criteria were body mass index (BMI) >30 kg/m2 and HbA1c ranging from 5.7 to 6.4. Body
weight, BMI, and HbA1c were assessed for each patient preprocedure and at 6 months postprocedure. Statistical analysis was performed
using a paired sample t test.
Results: The baseline mean body weight, BMI, and HbA1c were 107.4 ± 12.8 kg, 37.4 ± 3.3 kg/m2, and 6 ± 0.2, respectively.
Concerning complications, no serious adverse events were detected. Six months after the procedure, the mean body weight and BMI
significantly decreased to 98 ± 11.6 kg and 34.1 ± 3 kg/m2, respectively (P < .0001). A paired sample t test showed a significant
reduction in HbA1c from pre- to postprocedure (6.1 ± 0.2 preprocedure vs 4.7 ± 0.6 postprocedure, P < .0001). The mean percent
reductions in body weight, BMI, and HbA1c were 8.9% ± 1.2, 8.8% ± 1, and 21.4% ± 8.9, respectively. A statistically significant
positive correlation was found between BMI and HbA1c after the procedure (r ¼ 0.91, P ¼ .0002).
Conclusions: LGAE is well tolerated and leads to clinically significant decreases in weight and HbA1c in obese, prediabetic patients. |
